Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 365

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 7
Chunk 365
---
61
    %

    Net income (loss)
     
    $
    235,239

    $
    (535,977
    )
     
    $
    771,216

    NM*

    Earnings (loss) per share:

    Basic
     
    $
    2.47

    $
    (5.80
    )
     
    $
    8.27

    NM*

    Diluted
     
    $
    2.34

    $
    (5.80
    )
     
    $
    8.14

    NM*

* NM: not meaningful

Revenues

The following table summarizes the components of our net product revenues, by product, for the periods indicated:

    For the Year Ended December 31,

    2024

    2023

    Change

    Change

    (in thousands)

    $

    %

    PMO Products
     
    $
    967,169

    $
    944,520

    $
    22,649

    2
    %

    ELEVIDYS

    820,791

    200,356

    620,435

    NM*

    Products, net
     
    $
    1,787,960

    $
    1,144,876

    $
    643,084

    56
    %

* NM: not meaningful

Net product revenues for our products for 2024 increased by $643.1 million, or 56%, compared with 2023. The increase primarily reflects an increase in net product revenues of ELEVIDYS of $620.4 million in 2024 as a result of its initial FDA approval in June 2023 and subsequent expanded label approval in June 2024.

The following table summarizes the components of our collaboration and other revenues for the periods indicated:

-74-

    For the Year Ended December 31,

    2024

    2023

    Change

    Change

    (in thousands)

    $

    %

    Contract manufacturing
     
    $
    49,038

    $
    9,216

    $
    39,822

    NM*

    Amortization of performance obligations**

    48,000

    89,244

    (41,244
    )

    (46
    )%

    Royalty revenue

    16,981

    —